EGFR and lung cancer: A reversible tolerant state to osimertinib, an EGFR inhibitor, was driven by miR-147b, the foremost overexpressed miRNA in both EGFR-mutated and osimertinib-tolerant lung cancer cells, by suppressing succinate dehydrogenase and VHL that linked to the pseudohypoxia and tricarboxylic acid cycle (TCA) pathways [77].